MMS › analyze
MMS · Analyze
Price $57.59 · MktCap $3.02B · ~$1.22B net debt · Beta 0.59 · Div 2.29% (19% payout) Government BPO: administers health & human services — Medicaid/CHIP & ACA eligibility/enrollment, VA disability medical exams (VES), federal student-loan servicing (Aidvantage), UK/Australia welfare-to-work. FY ends Sept 30.
Verdict: WATCH (accumulate on weakness / on book-to-bill confirmation) · Conviction 6.0/10 · Fair value $70–85
A genuinely cheap, cash-gushing government annuity where the headline scare (the "VA contract hit") is temporary and mechanical — but the real question is a 0.5x book-to-bill that says the backlog is shrinking while AI and DOGE erode the forward base. FCF and margins are rising today even as the top line stalls. That can be a great value entry or a slow-melting yield; the leading indicator decides which, so this is a WATCH with an accumulate tilt, not a table-pound buy.
⚠️ The scare, right-sized: the "VA contract hit" is a temporary incentive pause, not a lost contract
The Zacks headlines overstate it. The VA suspended the performance incentive/disincentive mechanism on the Medical Disability Exam (MDE) program July 1 – Dec 31, 2026 — a 6-month pause of the timeliness/quality bonus, not a contract loss or scope cut. Maximus's VES subsidiary retained MDE Regions 1–4 (re-awarded, effective Jan 2025). Impact: ~$0.35 off FY26 adjusted EPS, and it reverses in FY27 when incentives can resume. This is the proximate trigger for the guidance cut and much of the 42% drawdown — and it is the most fixable part of the bear case.
1. Fundamentals — cheap, cash-rich, but growth is stalling
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Read |
|---|---|---|---|---|---|
| Revenue | $4.63B | $4.90B | $5.31B | $5.43B | 3yr CAGR 5.5%; FY26 guided $5.2–5.35B = a decline ⚠️ |
| Operating inc | $315M | $295M | $489M | $528M | Margin recovered to 13% (Medicaid unwinding normalized) |
| Net income | $204M | $162M | $307M | $319M | 3yr CAGR 16% |
| EPS (dil) | $3.29 | $2.63 | $4.99 | $5.51 | Buyback-amplified |
| FCF | $234M | $224M | $401M | $366M | FY26 guided $425–475M — rising |
| Cash / Debt | $41M/$1.51B | $65M/$1.43B | $183M/$1.28B | $222M/$1.44B | Net debt ~$1.22B, ~1.6–1.8x EBITDA — manageable |
| Dil. shares | 62.0M | 61.5M | 61.5M | 57.9M | Buyback retired ~9% in FY25 |
- FCF yield ~11% trailing, ~15% on FY26 guide — exceptional for a stable-cash business, and FCF is guided up despite the revenue dip.
- Capital allocation is buyback-first: $447M repurchased in FY25 (~9% of shares), $400M reauthorized May 2026 (~13% of the cap at $57), $192M done YTD FY26. The dividend (2.29% yield, 19% payout) is very safe but flat — total dividends have been ~$68–73M for four straight years. Treat this as a value/buyback stock, not a dividend grower.
- ⚠️ No asset floor: stated BVPS $33 is inflated by $1.78B goodwill; tangible book is negative (~−$110M). The value is the FCF stream, not the balance sheet — so Graham IV ($71) overstates and is not weighted.
2. Moat — Narrow (evergreen 4/10)
- Real but shallow. Incumbency inertia (an agency mid-program faces continuity-of-benefits political risk + re-accreditation cost, so mid-contract switching is rare), past-performance qualifications + security clearances that gate the bidder pool, and HHS-eligibility scale few peers match. But this is contract-level stickiness, not pricing power — 26% gross / 13% operating margins confirm a labor-cost pass-through, not a toll road. ROIC low-teens ≈ marginal excess over WACC.
- The recompete treadmill is the defining structural risk. Maximus must re-win essentially all its revenue every ~5 years, increasingly on price. It retained the VA MDE regions — but on a 1-year base + single option year (~2 years), far shorter and lower-visibility than the original multi-year award, and now shared with Leidos/UnitedHealth/Loyal Source. Retention, yes — on weaker terms.
- Competitive set: wins on HHS eligibility/enrollment + citizen-CX scale (its defensible niche vs GDIT/Leidos, who are IT/defense-first); exposed where work is generic BPO/IT-modernization (Accenture Federal, Deloitte, Conduent, ICF, and mandated 8(a)/set-aside small businesses all pressure price).
3. The two-sided AI story — and why it flatters trailing cash
Maximus's core delivery (call-center seats, claims/eligibility processing) is exactly what generative AI automates. Two opposite effects, both real: - Near-term tailwind (happening now): its FedRAMP-authorized "Total Experience Management"/Accuracy Assistant automates its own delivery — Federal segment op margin hit 18.6% in Q3 and is guided higher, and 75–80% of new bids carry AI criteria. This is why FCF and margins rise while revenue dips. - Terminal threat: automating a labor-arbitrage business expands margin on a contracting top line. If agencies need fewer BPO seats (or in-source with AI), the per-transaction/per-seat base Maximus is paid to service shrinks. This is value-per-contract compression — and it is why an 11% trailing FCF yield could be a slowly-melting yield rather than a bargain.
4. Sentiment & the decisive number
- Q3 FY26 (qtr end Jun 30): revenue $1.28B, adj EPS $2.22 (beat), adj EBITDA margin 15.0%. FY26 guidance cut to adj EPS $7.90–8.20 (the ~$0.35 VA pause), revenue $5.2–5.35B held, FCF $425–475M.
- 🚩 The single most concerning metric: TTM book-to-bill 0.5x. YTD signed awards $1.25B, awarded-but-unsigned $1.35B — well below 1.0, i.e. backlog is contracting. Pipeline is large ($50.4B, $2.86B submitted) but conversion is weak. This is the leading indicator that governs whether the cheapness is value or a trap.
- Federal exposure ~56% of revenue — the structural DOGE/budget-cut overhang. Q1 FY26 Federal grew just +0.8%. No confirmed large cancellations yet, but the soft book-to-bill signals demand softness.
- Medicaid redetermination volumes are recovering (a margin/volume tailwind, not a rolloff) — one worry that's stabilizing.
- Analysts: mean target ~$92.50 vs $57.59 (~60% gap), but 17 recently cut PTs; bear thesis = backlog/DOGE, bull = 8.5x PE + 11% FCF yield. Beta 0.59 — defensive.
5. Valuation — cheap, with a conservative fair value well above spot
Type: government-services value stock, safe-but-flat dividend, buyback-driven. Use FCF yield, P/E, EV/EBITDA. Graham not weighted (negative tangible book).
| Model | Input | Output |
|---|---|---|
| Fwd P/E | ~$8.05 FY26 adj EPS | 6.9x — deep trough |
| EV/EBITDA | ~$730M EBITDA | 6.8x |
| FCF yield | $450M FY26 ÷ $3.02B | ~15% (11% trailing) |
| Bogle | 2.3% div + ~3–5% buyback + 0–2% organic + multiple normalization | high if multiple re-rates |
Fair value $70–85 (midpoint ~$77): - 9–11x FY26 adj EPS ($8.05): $72–88 · 7–8x EV/EBITDA less net debt: $71–84 · 10–12x FCF less net debt: $60–77.
At $57.59 the stock is ~25–35% below a conservative fair value, plus a 2.3% dividend and a ~13%-of-cap buyback authorization. The $92.50 analyst mean assumes growth resumes — I anchor the more defensible $70–85.
Synthesis & verdict
For a mature, cash-generative contractor at a trough multiple, the framework weights Fundamentals + Valuation over Moat — and those are strongly favorable: rising FCF, 6.9x fwd earnings, ~15% forward FCF yield, aggressive buyback, a temporary and reversing VA hit, and recovering Medicaid margins. That's a real margin of safety.
But two things hold conviction below a clear BUY: the narrow moat (evergreen 4) on a business that must perpetually re-win its revenue, and the 0.5x book-to-bill — a genuine forward-revenue warning that AI and DOGE could turn the high FCF yield into a melting-ice-cube yield. The tell to watch is whether that ratio recovers toward 1.0 as the $50B pipeline converts.
Net: cheap enough that even modest erosion + buyback produces acceptable returns, with a temporary catalyst already priced in — but not a table-pound buy while the backlog is shrinking. A small starter here is defensible; sizing up should wait for book-to-bill confirmation.
Conviction 6.0/10.
- Entry: attractive at $57.59; add sub-$53 (near the 52-wk low). Trim: 11x fwd (~$92, where it re-rates to a normal government-services multiple).
- ↑ to ACCUMULATE/BUY (7+): TTM book-to-bill back above ~0.9–1.0, VA incentives resume in FY27, no DOGE cancellations.
- ↓ to AVOID: book-to-bill stays sub-0.6 for another quarter, a large federal contract cancelled, or revenue guided down again for FY27.
A portfolio-specific passage was removed from the public build.